Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation

Jorge Vela-Ojeda, Laura Montiel-Cervantes, Perla Granados-Lara, Elba Reyes-Maldonado, Ethel García-Latorre, Jaime Garcia-Chavez, Abraham Majluf-Cruz, Hector Mayani, Jose R. Borbolla-Escoboza, Miriam García Ruiz Esparza

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for some hematological diseases; however, graft-versus-host disease (GVHD) is still one of the most important and deleterious complications. Regulatory T cells and iNKT cells can decrease the incidence and severity of GVHD, while preserving the graft-versus-tumor response. In order to analyze the relationship between the transfused dose of these cells, the presence of GVHD and survival, 15 normal donors and 15 patients with hematological diseases who underwent allogeneic HSCT from HLA-identical siblings were studied. The mobilization and infused doses of v24-v11(iNKT cells) lymphocytes and CD4+CD25+FoxP3+, CD4+CD25+FoxP3+CD62L+, regulatory T cells were analyzed. All patients were conditioned with busulfan and cyclophosphamide and received cyclosporine and methotrexate as GVHD prophylaxis. iNKT and FoxP3 cells were mobilized after G-CSF administration. Acute GVHD was present in 9 of 15 (60%) and cGVHD in 7 of 13 (54%) patients. Patients who received a dose <0.6 × 106/kg of iNKT cells and >4 × 106/kg of FoxP3 had better disease-free survival and overall survival. Individuals transfused with >1.1 × 106/kg of FoxP3+ CD62L+ Treg cells had better overall survival. In conclusion, iNKT and Treg cells are mobilized with G-CSF in healthy donors and the dose of iNKT cells and FoxP3 and CD62L+ regulatory T cells is of clinical importance in human HSCT. © Mary Ann Liebert, Inc. 2010.
Original languageAmerican English
Pages (from-to)333-340
Number of pages298
JournalStem Cells and Development
DOIs
StatePublished - 1 Mar 2010

Fingerprint

Natural Killer T-Cells
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Regulatory T-Lymphocytes
Hematologic Diseases
Granulocyte Colony-Stimulating Factor
Survival
Tissue Donors
Busulfan
Methotrexate
Cyclophosphamide
Cyclosporine
Disease-Free Survival
Siblings
Lymphocytes
Transplants
Incidence
Neoplasms

Cite this

Vela-Ojeda, Jorge ; Montiel-Cervantes, Laura ; Granados-Lara, Perla ; Reyes-Maldonado, Elba ; García-Latorre, Ethel ; Garcia-Chavez, Jaime ; Majluf-Cruz, Abraham ; Mayani, Hector ; Borbolla-Escoboza, Jose R. ; Esparza, Miriam García Ruiz. / Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. In: Stem Cells and Development. 2010 ; pp. 333-340.
@article{af2218ec5a6b4e0abd7bcd8b9f8789f2,
title = "Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for some hematological diseases; however, graft-versus-host disease (GVHD) is still one of the most important and deleterious complications. Regulatory T cells and iNKT cells can decrease the incidence and severity of GVHD, while preserving the graft-versus-tumor response. In order to analyze the relationship between the transfused dose of these cells, the presence of GVHD and survival, 15 normal donors and 15 patients with hematological diseases who underwent allogeneic HSCT from HLA-identical siblings were studied. The mobilization and infused doses of v24-v11(iNKT cells) lymphocytes and CD4+CD25+FoxP3+, CD4+CD25+FoxP3+CD62L+, regulatory T cells were analyzed. All patients were conditioned with busulfan and cyclophosphamide and received cyclosporine and methotrexate as GVHD prophylaxis. iNKT and FoxP3 cells were mobilized after G-CSF administration. Acute GVHD was present in 9 of 15 (60{\%}) and cGVHD in 7 of 13 (54{\%}) patients. Patients who received a dose <0.6 × 106/kg of iNKT cells and >4 × 106/kg of FoxP3 had better disease-free survival and overall survival. Individuals transfused with >1.1 × 106/kg of FoxP3+ CD62L+ Treg cells had better overall survival. In conclusion, iNKT and Treg cells are mobilized with G-CSF in healthy donors and the dose of iNKT cells and FoxP3 and CD62L+ regulatory T cells is of clinical importance in human HSCT. {\circledC} Mary Ann Liebert, Inc. 2010.",
author = "Jorge Vela-Ojeda and Laura Montiel-Cervantes and Perla Granados-Lara and Elba Reyes-Maldonado and Ethel Garc{\'i}a-Latorre and Jaime Garcia-Chavez and Abraham Majluf-Cruz and Hector Mayani and Borbolla-Escoboza, {Jose R.} and Esparza, {Miriam Garc{\'i}a Ruiz}",
year = "2010",
month = "3",
day = "1",
doi = "10.1089/scd.2009.0216",
language = "American English",
pages = "333--340",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",

}

Vela-Ojeda, J, Montiel-Cervantes, L, Granados-Lara, P, Reyes-Maldonado, E, García-Latorre, E, Garcia-Chavez, J, Majluf-Cruz, A, Mayani, H, Borbolla-Escoboza, JR & Esparza, MGR 2010, 'Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation', Stem Cells and Development, pp. 333-340. https://doi.org/10.1089/scd.2009.0216

Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. / Vela-Ojeda, Jorge; Montiel-Cervantes, Laura; Granados-Lara, Perla; Reyes-Maldonado, Elba; García-Latorre, Ethel; Garcia-Chavez, Jaime; Majluf-Cruz, Abraham; Mayani, Hector; Borbolla-Escoboza, Jose R.; Esparza, Miriam García Ruiz.

In: Stem Cells and Development, 01.03.2010, p. 333-340.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation

AU - Vela-Ojeda, Jorge

AU - Montiel-Cervantes, Laura

AU - Granados-Lara, Perla

AU - Reyes-Maldonado, Elba

AU - García-Latorre, Ethel

AU - Garcia-Chavez, Jaime

AU - Majluf-Cruz, Abraham

AU - Mayani, Hector

AU - Borbolla-Escoboza, Jose R.

AU - Esparza, Miriam García Ruiz

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for some hematological diseases; however, graft-versus-host disease (GVHD) is still one of the most important and deleterious complications. Regulatory T cells and iNKT cells can decrease the incidence and severity of GVHD, while preserving the graft-versus-tumor response. In order to analyze the relationship between the transfused dose of these cells, the presence of GVHD and survival, 15 normal donors and 15 patients with hematological diseases who underwent allogeneic HSCT from HLA-identical siblings were studied. The mobilization and infused doses of v24-v11(iNKT cells) lymphocytes and CD4+CD25+FoxP3+, CD4+CD25+FoxP3+CD62L+, regulatory T cells were analyzed. All patients were conditioned with busulfan and cyclophosphamide and received cyclosporine and methotrexate as GVHD prophylaxis. iNKT and FoxP3 cells were mobilized after G-CSF administration. Acute GVHD was present in 9 of 15 (60%) and cGVHD in 7 of 13 (54%) patients. Patients who received a dose <0.6 × 106/kg of iNKT cells and >4 × 106/kg of FoxP3 had better disease-free survival and overall survival. Individuals transfused with >1.1 × 106/kg of FoxP3+ CD62L+ Treg cells had better overall survival. In conclusion, iNKT and Treg cells are mobilized with G-CSF in healthy donors and the dose of iNKT cells and FoxP3 and CD62L+ regulatory T cells is of clinical importance in human HSCT. © Mary Ann Liebert, Inc. 2010.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for some hematological diseases; however, graft-versus-host disease (GVHD) is still one of the most important and deleterious complications. Regulatory T cells and iNKT cells can decrease the incidence and severity of GVHD, while preserving the graft-versus-tumor response. In order to analyze the relationship between the transfused dose of these cells, the presence of GVHD and survival, 15 normal donors and 15 patients with hematological diseases who underwent allogeneic HSCT from HLA-identical siblings were studied. The mobilization and infused doses of v24-v11(iNKT cells) lymphocytes and CD4+CD25+FoxP3+, CD4+CD25+FoxP3+CD62L+, regulatory T cells were analyzed. All patients were conditioned with busulfan and cyclophosphamide and received cyclosporine and methotrexate as GVHD prophylaxis. iNKT and FoxP3 cells were mobilized after G-CSF administration. Acute GVHD was present in 9 of 15 (60%) and cGVHD in 7 of 13 (54%) patients. Patients who received a dose <0.6 × 106/kg of iNKT cells and >4 × 106/kg of FoxP3 had better disease-free survival and overall survival. Individuals transfused with >1.1 × 106/kg of FoxP3+ CD62L+ Treg cells had better overall survival. In conclusion, iNKT and Treg cells are mobilized with G-CSF in healthy donors and the dose of iNKT cells and FoxP3 and CD62L+ regulatory T cells is of clinical importance in human HSCT. © Mary Ann Liebert, Inc. 2010.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77949633792&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=77949633792&origin=inward

U2 - 10.1089/scd.2009.0216

DO - 10.1089/scd.2009.0216

M3 - Article

C2 - 19919293

SP - 333

EP - 340

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

ER -